Cortex Business Solutions has a 94 per cent upside, Beacon Securities says

Cortex CEO Joel Leetzow
E-invoicing company Cortex Business Solutions (Cortex Stock Quote, Chart TSXV:CBX) is starting to see the benefits of its Powervision acquisition, says analyst Gabriel Leung of Beacon Securities, who on Friday upped his target price in response to the company’s recently released earnings.

Calgary-based Cortex Business Solutions reported its fiscal first quarter 2019 financials last week, producing revenue and EBITDA of $3.3 million and $643,000, respectively, with President and CEO Joel Leetzow pointing to the gains made through acquiring software company Powervision, a $7-million deal which closed this past September.

“With our first months now behind us after the Powervision acquisition, we are already starting to see the synergies that we had expected from combining the two companies,” said Leetzow, in a press release. “We have made two new sales of the complete Cortex platform since the acquisition and our pipeline for the combined solution is growing rapidly.”

The Q1 top and bottom lines came in slightly above Leung’s estimates, which were $3.1 million and $466,000, respectively. Drilling down, Leung highlighted the company’s recurring access and usage fees which were up 16 per cent year-over-year to $3.3 million, with 97 buyers in the network (down from 99 last quarter) and active suppliers at 9,386 (up from 9,160 last quarter.

“Overall, we think fiscal Q1 was a strong start to the Powervision integration both in terms of financials and new customer and pipeline signups,” says Leung, in an update to clients last week. “We are maintaining our Buy rating, but increasing our target price to $7.00 (was $6.50), which is based on 15x FY20e EV/EBITDA.”

Leung’s $7.00 target represented a 94 per cent projected return on investment as of publication date.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: cbx
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Uber stock a buy? (May, 2024)

Following the release of the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on… [Read More]

8 hours ago

Trulieve scores price target raise at Echelon

Following the company's most recent results, Echelon Capital Markets analyst Andrew Semple has raised his price target on Trulieve Cannabis… [Read More]

14 hours ago

Is Green Thumb Industries a buy? (May, 2024)

Its first quarter numbers are in the books and Beacon Securities analyst Russell Stanley is still bullish on Green Thumb… [Read More]

1 day ago

Is TKO stock a buy?

Following the company's first quarter results, Roth MKM analyst Eric Handler has maintained his "Buy" rating on TKO Group (TKO… [Read More]

1 day ago

Is WELL Health stock a buy? (May, 2024)

Following the company's first quarter results, Eight Capital analyst Christian Sgro thinks there is a lot of money to be… [Read More]

1 day ago

“You Never Get Fired for Buying Shopify”

Its first quarter results are in the books and ATB Capital Markets analyst Martin Toner has become bullish on Shopify… [Read More]

2 days ago